Medication-Assisted Treatment (MAT): Medication Plus Therapy for Recovery
FDA-approved medication paired with counseling to support recovery from opioid and alcohol use disorder
What Is Medication-Assisted Treatment?
Medication-assisted treatment (MAT) pairs FDA-approved medication with counseling and behavioral support to treat substance use disorders. This whole-person approach addresses both the physical and psychological sides of addiction at once, and research consistently links it to better outcomes and a lower risk of overdose.
The Science Behind MAT
MAT works on the brain's opioid receptors — the same ones affected by heroin and prescription painkillers. Depending on the medication, it can activate those receptors to prevent withdrawal (agonists), partially activate them to ease cravings (partial agonists), or block them entirely so opioids can't produce their usual effect (antagonists).
This gives the brain time to heal while a person engages in therapy and rebuilds daily life. Rather than "replacing one drug with another," MAT medications are dosed carefully to steady brain chemistry without producing euphoria, so people can function normally while they recover.
Mat Vs Moud
You may come across a few different terms for this approach. MAT (medication-assisted treatment) is the term most people know, and it emphasizes pairing medication with therapy. MOUD (medications for opioid use disorder) is a newer term that centers the medications themselves, reflecting evidence that they're effective treatment on their own, not just "assistance."
You may also see MAUD (medications for alcohol use disorder), which refers to FDA-approved medications for alcohol addiction specifically. Whatever the label, the evidence points the same direction: medication paired with behavioral care produces the strongest outcomes.
How MAT Fits Into Treatment
MAT works best paired with comprehensive behavioral support — individual counseling, group therapy, and help with practical issues like housing, employment, and family relationships.
Treatment Process
Treatment usually starts with an assessment to determine the right medication and dose. For buprenorphine, a person needs to be in mild-to-moderate withdrawal before starting, to avoid precipitated withdrawal. Methadone can start right away. Naltrexone requires finishing detox first.
Once stabilized on medication, patients continue with ongoing counseling — typically Cognitive Behavioral Therapy (CBT) and/or Motivational Interviewing — to work through the psychological side of addiction and build coping skills that last.
FDA-Approved Medications Used in MAT
Three medications are FDA-approved for opioid use disorder, and three more for alcohol use disorder. Each works differently and fits different patients and situations.
Opioid Medications
Buprenorphine (Suboxone, Subutex, Sublocade) is a partial opioid agonist that eases cravings and withdrawal without producing the full effects of opioids. Its "ceiling effect" means taking more doesn't increase the effect past a certain point, which makes it safer than full agonists. It's available as sublingual film, tablets, or a monthly injection. Read more about how buprenorphine-based options work .
Methadone is a full opioid agonist that prevents withdrawal and eases cravings at the correct dose. It has a long track record (in use since 1972) and a deep evidence base. Methadone is dispensed only through certified Opioid Treatment Programs (OTPs), which typically means daily clinic visits at the start. See how methadone dosing programs are structured .
Naltrexone (Vivitrol) is an opioid antagonist that blocks opioid effects completely. Available as a daily pill or monthly injection, naltrexone requires a full detox first (7-14 days opioid-free). It carries no abuse potential and can be prescribed in any medical office. Learn more about Vivitrol.
Alcohol Medications
Naltrexone (ReVia, Vivitrol) reduces the rewarding effect of alcohol and lowers cravings. It's available as a daily pill or monthly injection, and some patients use "targeted" dosing — taking it ahead of situations where drinking is likely.
Acamprosate (Campral) helps restore balance to brain systems disrupted by long-term alcohol use. It works best for maintaining abstinence once drinking has already stopped, and pairs well with counseling and support groups.
Disulfiram (Antabuse) creates an unpleasant reaction — nausea, headache, flushing — if alcohol is consumed. This aversive approach tends to work best for highly motivated patients, often in settings where taking the medication can be verified.
What the Research Shows About MAT
Research consistently points to better outcomes across several measures with MAT:
- 50% or greater reduction in overdose deaths compared to abstinence-only care
- Better treatment retention—people stay in treatment longer and are more likely to complete it
- Less illicit drug use—70% or greater reduction in opioid use
- Less criminal activity—reduced drug-seeking behavior and related crime
- Improved employment outcomes—more patients able to keep working
- Lower HIV/Hepatitis C transmission—less injection drug use
- Better birth outcomes—for pregnant women with OUD
Common MAT Myths, Addressed
Despite strong evidence, MAT still runs into myths and stigma. Here's what the research actually shows:
Myth Busting
"MAT just trades one addiction for another." This is the most common myth. Addiction means compulsive use despite harm. MAT medications, taken as prescribed, don't produce euphoria or impair function — they steady brain chemistry so people can work, care for family, and rebuild their lives.
"You're not really in recovery if you're on MAT." The medical community and major recovery organizations recognize that taking prescribed medication for a medical condition isn't the same as active addiction. Many people on MAT are active members of 12-step programs and other recovery communities.
"MAT should only be short-term." Research shows longer treatment duration tends to correlate with better outcomes. Stopping MAT too soon is linked to higher relapse rates and greater overdose risk. Many patients do best on indefinite maintenance, much like medication for any other chronic condition.
Who Tends to Benefit Most from MAT?
MAT is recommended for anyone diagnosed with opioid use disorder (OUD) or alcohol use disorder (AUD) who meets clinical criteria. That said, certain groups tend to see especially strong outcomes:
- People with moderate-to-severe opioid use disorder — including those affected by heroin, fentanyl, or prescription painkillers. MAT is the first-line recommended approach for OUD
- Anyone who has relapsed after abstinence-only care — research shows adding medication meaningfully lowers relapse rates compared to behavioral treatment alone
- People at high overdose risk — especially those returning to use after a period of abstinence (like after incarceration or detox), when tolerance is low and overdose risk spikes
- Pregnant women with opioid dependence — buprenorphine or methadone is the standard of care during pregnancy, protecting mother and baby from the dangers of withdrawal and continued use
- People with a co-occurring mental health condition — MAT can steady brain chemistry, helping patients engage more fully in therapy for depression, anxiety, PTSD, and other conditions
- Those managing alcohol dependence — naltrexone and acamprosate help lower cravings and support sobriety, especially alongside counseling
There's no single "typical" MAT patient — people of every age, background, and severity level benefit. The decision to start should be made together with your provider, based on your medical history, patterns of use, and personal goals.
MAT Across Different Levels of Care
One of MAT's biggest strengths is flexibility — medication can fit into nearly every level of addiction treatment, keeping care continuous as patients move through recovery:
- Medical Detox — Buprenorphine or methadone is often used during detox to manage opioid withdrawal safely and more comfortably. This is frequently where MAT begins
- Residential/Inpatient Treatment — Many residential programs now build in MAT, letting patients stabilize on medication while receiving intensive therapy — addressing the physical and psychological sides of addiction together
- Partial Hospitalization (PHP) — Patients attend structured daytime treatment while continuing MAT. This level suits people stepping down from residential care who still need significant support
- Intensive Outpatient (IOP) — MAT paired with IOP gives flexibility to patients balancing work or family obligations, attending sessions several times a week while staying on medication
- Standard Outpatient — The most common long-term setting for MAT, with periodic provider visits (often monthly once stable) plus ongoing counseling. Naltrexone-based options like Vivitrol fit especially well here
- Telehealth — Since 2023 regulatory changes, buprenorphine can be prescribed via telehealth without an in-person visit first, expanding access for people in rural areas or facing transportation barriers
The key principle is continuity — patients should keep taking MAT medication as they move between levels of care. Interrupting medication during these transitions is one of the leading causes of relapse and overdose. A well-run program keeps medication management seamless at every step.
Need Help Finding the Right Care?
Browse our directory or call to discuss your care options.
Quick Answers: Medication-Assisted Treatment
Resources & Further Reading
Ready to Take the Next Step?
Browse WA programs offering medication-assisted treatment to find the right fit for your mental health and recovery journey.
